Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/21/2010US20100268329 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease
10/21/2010US20100268321 Drug-releasing graft
10/21/2010US20100267946 Prodrugs of gaba analogs, compositions and uses thereof
10/21/2010US20100267941 Irna agents with biocleavable tethers
10/21/2010US20100267924 Phosphorus-Containing Compounds with Polymeric Chains, and Methods of Making and Using the Same
10/21/2010US20100267842 Emulsions of Perfluorocarbons
10/21/2010US20100267841 Composition for Topical Use Containing an Extract of Stryphnodendron; Its Preparation As Well As Its Application
10/21/2010US20100267839 Diarylalkanes as potent inhibitors of binuclear enzymes
10/21/2010US20100267838 Pulverulent carotenoid preparation for colouring drinks
10/21/2010US20100267837 Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants
10/21/2010US20100267836 Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
10/21/2010US20100267835 Methods of treating disorders of trigeminalvascular activation
10/21/2010US20100267834 Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning
10/21/2010US20100267833 Compositions and methods for preventing or treating an inflammatory response
10/21/2010US20100267832 Method for treating macular degeneration
10/21/2010US20100267831 Amino Acid-Containing Composition for Preventing or Remedying Decrease in the Skeletal Muscle of Aged People
10/21/2010US20100267830 Methods and compositions for promoting the neurological development of an infant
10/21/2010US20100267829 Pharmaceutical composition comprising low concentrations of environment pollutants
10/21/2010US20100267828 dha derivatives and their use as medicaments
10/21/2010US20100267827 Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
10/21/2010US20100267826 Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
10/21/2010US20100267825 Treatment of skin damage
10/21/2010US20100267824 Stable oxaliplatin composition for parenteral administration
10/21/2010US20100267823 Aurones as selective pde inhibitors and their use in neurological conditions and disorders
10/21/2010US20100267822 Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
10/21/2010US20100267821 Prophylactic or therapeutic agent for irritable bowel syndrome
10/21/2010US20100267820 Antiadhesion agents
10/21/2010US20100267819 Pharmaceutical composition for diabetic nephropathy and its preparation and application
10/21/2010US20100267818 Stabilized single-liquid pharmaceutical composition containing docetaxel
10/21/2010US20100267817 Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
10/21/2010US20100267816 Human anti-amyloid beta peptide antibody and fragment of said antibody
10/21/2010US20100267815 PFKFB4 Inhibitors And Methods Of Using The Same
10/21/2010US20100267814 Targeting MicroRNAs for the Treatment of Liver Cancer
10/21/2010US20100267813 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
10/21/2010US20100267811 RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
10/21/2010US20100267810 Methods and compositions for treating neurological disease
10/21/2010US20100267809 Double stranded nucleic acid targeting low copy promoter-specific rna
10/21/2010US20100267808 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
10/21/2010US20100267807 Alleviating neuropathic pain with eets and seh inhibitors
10/21/2010US20100267806 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
10/21/2010US20100267805 Targeting opposite strand replication intermediates of single-stranded viruses by rnai
10/21/2010US20100267804 Differential expression of micrornas in nonfailing versus failing human hearts
10/21/2010US20100267803 Regulators Of Fat Metabolism As Anti-Cancer Targets
10/21/2010US20100267802 Delivery method
10/21/2010US20100267801 Cyclohexyl sulphones for treatment of cancer
10/21/2010US20100267800 N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses
10/21/2010US20100267799 Orodispersible pharmaceutical composition of perindopril
10/21/2010US20100267798 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/21/2010US20100267796 Therapeutic agent for irritable bowel syndrome
10/21/2010US20100267794 Anti-fatigue agent comprising amino acid composition
10/21/2010US20100267793 Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267792 Topical Compositions Containing Desthiobiotin and its Derivatives and a Method of Treating Skin
10/21/2010US20100267789 Tablet formulations comprising valsartan
10/21/2010US20100267788 Dual-acting antihypertensive agents
10/21/2010US20100267787 Pharmaceutical Compositions
10/21/2010US20100267786 Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitor
10/21/2010US20100267785 Candesartan cilexetil
10/21/2010US20100267784 Novel 4,5-dihydroisoxazoles with estrogenic activity
10/21/2010US20100267783 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
10/21/2010US20100267782 Sodium channel inhibitors
10/21/2010US20100267781 Naphthalene-based inhibitors of anti-apoptotic proteins
10/21/2010US20100267780 Bicyclic aryl and heteroaryl receptor modulators
10/21/2010US20100267779 Novel Compounds and Methods of Using Them
10/21/2010US20100267778 Diphenyl ether compound, process for producing the same, and use
10/21/2010US20100267777 Treatment of cancers with acquired resistance to kit inhibitors
10/21/2010US20100267776 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
10/21/2010US20100267775 Oxadiazolidinedione compound
10/21/2010US20100267774 P38 map kinase inhibitors
10/21/2010US20100267773 Estrogen receptor ligands and methods of use thereof
10/21/2010US20100267772 Combination of a Serotonin Reuptake Inhibitor and Agomelatine
10/21/2010US20100267771 Automated immunossay apparatus with flexible pick-up arm
10/21/2010US20100267769 Substituted Bicyclocarboxyamide Compounds
10/21/2010US20100267768 Process for making modulators of cystic fibrosis transmembrane conductance regulator
10/21/2010US20100267767 Nuclear receptor binding agents
10/21/2010US20100267766 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
10/21/2010US20100267765 Pharmaceutical Compositions and Methods for CCR5 Antagonists
10/21/2010US20100267764 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
10/21/2010US20100267763 Method of Decreasing Pro-ADAM10 Secretase and/or Beta Secretase Levels
10/21/2010US20100267762 Novel p2x7r antagonists and their use
10/21/2010US20100267761 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
10/21/2010US20100267760 Methods of and Combination Therapies for Treating or Delaying the Onset of Dyskinesia
10/21/2010US20100267759 INHIBITORS OF Akt ACTIVITY
10/21/2010US20100267758 Pharmaceutical formulation
10/21/2010US20100267757 Aminothiazoles and their uses
10/21/2010US20100267756 Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system
10/21/2010US20100267755 Pyrimidine derivatives
10/21/2010US20100267754 Integrin expression inhibitor
10/21/2010US20100267753 Methods of treating disorders associated with protein kinase ck2 activity
10/21/2010US20100267752 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267751 Pharmaceutical compositions and methods of treating dry eye disorders
10/21/2010US20100267750 Methods and compositions for treating pain
10/21/2010US20100267749 Trisubstituted furopyrimidines and use thereof
10/21/2010US20100267748 HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267747 5-(Arylsulfonyl)-Pyrazolopiperidines
10/21/2010US20100267746 Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
10/21/2010US20100267745 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents
10/21/2010US20100267744 Pharmaceutical Compositions
10/21/2010US20100267743 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
10/21/2010US20100267742 Combination targeted therapy for lung cancer
10/21/2010US20100267741 Compounds, Compositions and Methods Comprising Pyrazole Derivatives
1 ... 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 ... 7860